Nuvation Bio backs off from head-to-head brain cancer trialnews2025-11-04T10:33:54+00:00November 4th, 2025|Endpoints News|
Duchenne confirmatory trial fails, but Sarepta to ask FDA for full approval anywaysnews2025-11-04T00:20:06+00:00November 4th, 2025|Endpoints News|
UK regulators look to speed up how rare disease therapies reach the marketnews2025-11-03T17:24:47+00:00November 3rd, 2025|Endpoints News|
#ASH25: Lilly’s Jaypirca matches Imbruvica in Phase 3 early blood cancer trialnews2025-11-03T14:00:27+00:00November 3rd, 2025|Endpoints News|
#ASH25: Vertex, CRISPR say Casgevy shows promise in younger childrennews2025-11-03T14:00:17+00:00November 3rd, 2025|Endpoints News|
Tempero halts substance use disorder drug, is ‘assessing strategic alternatives’news2025-11-03T12:01:54+00:00November 3rd, 2025|Endpoints News|
Caribou says it’s cracked ‘off-the-shelf’ cell therapy, but needs to raise money to move forwardnews2025-11-03T12:00:16+00:00November 3rd, 2025|Endpoints News|
Roche, Manifold Bio to advance new brain shuttles in pact worth up to $2B+news2025-11-03T11:45:30+00:00November 3rd, 2025|Endpoints News|
Amgen Ventures joins $141M Series B for Italian gene therapy biotech AAVantgardenews2025-11-03T08:00:27+00:00November 3rd, 2025|Endpoints News|
Why are BridgeBio and Alnylam both seeing strong growth for their heart drugs?news2025-10-31T15:34:28+00:00October 31st, 2025|Endpoints News|
